ArticleBMC pulmonary medicine2026
A case report of unexpected rapid regression of diffuse pulmonary lymphangiomatosis mimicking advanced lung cancer.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiffuse pulmonary lymphangiomatosis (DPL) is an extremely rare lymphatic disorder characterized by diffuse proliferation of lymphatic vessels involving the lungs, pleura, and mediastinum. Its radiologic features often overlap with those of malignancy, particularly lymphangitic carcinomatosis, making accurate diagnosis challenging. CASE PRESENTATION: A 79-year-old man presented with a one-week history of dyspnea and high fever. Chest computed tomography demonstrated an enhancing pulmonary nodule with extensive mediastinal and bilateral hilar lymphadenopathy, pleural effusion, pleural thickening, and diffuse interlobular septal thickening, raising suspicion for advanced lung cancer with lymphangitic metastasis. Endobronchial ultrasound-guided transbronchial needle aspiration and pleural biopsy were nondiagnostic. Subsequently, video-assisted thoracoscopic surgery with wedge resection was performed. Histopathologic examination revealed diffuse proliferation of anastomosing lymphatic channels lined by endothelial cells, with positive immunostaining for D2-40 and CD31, consistent with DPL. Notably, without DPL-directed therapy, the patient's symptoms resolved within three weeks. Follow-up chest CT at two months demonstrated marked regression of lymphadenopathy and complete resolution of interlobular septal thickening. No clinical or radiological recurrence was observed during one year of follow-up.
conclusionDPL can closely mimic advanced lung cancer with lymphangitic metastasis on imaging while exhibiting a potentially reversible clinical course. Awareness of this entity is essential to avoid misdiagnosis and unnecessary aggressive treatment, particularly in atypical settings and for elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.